Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Nancy J. Tarbell, M.D.

Co-Author

This page shows the publications co-authored by Nancy Tarbell and Richard Gelber.
Connection Strength

0.359
  1. Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 1993 Jul 01; 72(1):261-70.
    View in: PubMed
    Score: 0.139
  2. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet. 1993 Jun 05; 341(8858):1428-32.
    View in: PubMed
    Score: 0.035
  3. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol. 1993 Apr; 11(4):616-22.
    View in: PubMed
    Score: 0.034
  4. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7.
    View in: PubMed
    Score: 0.019
  5. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60.
    View in: PubMed
    Score: 0.018
  6. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46.
    View in: PubMed
    Score: 0.016
  7. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22.
    View in: PubMed
    Score: 0.015
  8. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Aug; 16(8):2848-53.
    View in: PubMed
    Score: 0.012
  9. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95.
    View in: PubMed
    Score: 0.012
  10. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr; 12(4):740-7.
    View in: PubMed
    Score: 0.009
  11. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
    View in: PubMed
    Score: 0.009
  12. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 May; 10(5):810-7.
    View in: PubMed
    Score: 0.008
  13. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15; 78(10):2514-9.
    View in: PubMed
    Score: 0.008
  14. Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer. 1990 Dec 15; 66(12):2645-52.
    View in: PubMed
    Score: 0.007
  15. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990 Mar; 32(3):238-48.
    View in: PubMed
    Score: 0.007
  16. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601.
    View in: PubMed
    Score: 0.007
  17. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986 Sep 11; 315(11):657-63.
    View in: PubMed
    Score: 0.005
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.